286 related articles for article (PubMed ID: 9322878)
1. Clinical overview of the taxanes.
Goldspiel BR
Pharmacotherapy; 1997; 17(5 Pt 2):110S-125S. PubMed ID: 9322878
[TBL] [Abstract][Full Text] [Related]
2. Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
Sparano JA
Semin Oncol; 1998 Dec; 25(6 Suppl 13):10-5. PubMed ID: 9865686
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects.
D'Andrea GM; Seidman AD
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-27-S13-44. PubMed ID: 9335514
[TBL] [Abstract][Full Text] [Related]
4. Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer.
Ravdin PM
Semin Oncol; 1999 Jun; 26(3 Suppl 9):20-3. PubMed ID: 10426455
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer.
Ravdin PM
Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-18-S10-21. PubMed ID: 9275002
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel and docetaxel in breast and ovarian cancer.
Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
[TBL] [Abstract][Full Text] [Related]
7. Taxanes in combined-modality therapy for solid tumors.
Choy H
Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):23-38. PubMed ID: 10550824
[TBL] [Abstract][Full Text] [Related]
8. Taxanes in ovarian cancer treatment.
Seetalarom K; Kudelka AP; Verschraegen CF; Kavanagh JJ
Curr Opin Obstet Gynecol; 1997 Feb; 9(1):14-20. PubMed ID: 9090476
[TBL] [Abstract][Full Text] [Related]
9. The current status of docetaxel in solid tumors. An M. D. Anderson Cancer Center Review.
Hong WK
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):9-15. PubMed ID: 12108903
[TBL] [Abstract][Full Text] [Related]
10. Taxanes in the treatment of early breast cancer.
Ring AE; Ellis PA
Cancer Treat Rev; 2005 Dec; 31(8):618-27. PubMed ID: 16266787
[TBL] [Abstract][Full Text] [Related]
11. Recent progress in the clinical development of docetaxel (Taxotere).
Hortobagyi GN
Semin Oncol; 1999 Jun; 26(3 Suppl 9):32-6. PubMed ID: 10426457
[TBL] [Abstract][Full Text] [Related]
12. Taxoids: effective agents in anthracycline-resistant breast cancer.
Ravdin PM
Semin Oncol; 1995 Dec; 22(6 Suppl 13):29-34. PubMed ID: 8604450
[TBL] [Abstract][Full Text] [Related]
13. Taxoids: a new class of cytotoxic agents.
Marty M; Extra JM; Giacchetti S; Cuvier C; Espie M
Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S25-8. PubMed ID: 7909941
[TBL] [Abstract][Full Text] [Related]
14. Risks and benefits of taxanes in breast and ovarian cancer.
Michaud LB; Valero V; Hortobagyi G
Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
[TBL] [Abstract][Full Text] [Related]
15. The taxoids. Comparative clinical pharmacology and therapeutic potential.
Eisenhauer EA; Vermorken JB
Drugs; 1998 Jan; 55(1):5-30. PubMed ID: 9463787
[TBL] [Abstract][Full Text] [Related]
16. Integration of docetaxel into adjuvant breast cancer treatment regimens.
Hortobagyi GN
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):27-33. PubMed ID: 12108895
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview.
Hájek R; Vorlicek J; Slavik M
Neoplasma; 1996; 43(3):141-54. PubMed ID: 8841500
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel (Taxotere) in combination: a step forward.
Burris HA; Fields S; Peacock N
Semin Oncol; 1995 Dec; 22(6 Suppl 13):35-40. PubMed ID: 8604452
[TBL] [Abstract][Full Text] [Related]
19. The pharmacoeconomics of cancer therapies.
Bishop JF; Macarounas-Kirchman K
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-106-S19-111. PubMed ID: 9427279
[TBL] [Abstract][Full Text] [Related]
20. Evolution in the treatment of advanced breast cancer.
Crown J
Semin Oncol; 1998 Oct; 25(5 Suppl 12):12-7. PubMed ID: 9865706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
